Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

摘要

Despite the continuous introduction of novel agents inthe upfront treatment of multiple myeloma (MM), autologousstem cell transplantation (ASCT) remains a cardinalapproach for fit patients1. Both the durability anddepth of response post ASCT have been recognized asimportant prognostic factors2. Consolidation therapyfurther improves depth of response. However, there is noconsensus on the optimal regimen. Minimal residualdisease (MRD) negativity after treatment for newly diagnosedMM patients (NDMM) represents a strong prognosticfactor3. Therefore, MRD could guide treatmentdecisions. Βone health is of high importance for NDMMpatients as they are at high risk of developing skeletalrelatedevents (SREs) that impair quality of life4. Takingall the above factors into consideration, the aim of thisprospective study was to evaluate the efficacy, the safety,and the effect on bone metabolism of carfilzomib, lenalidomide,and dexamethasone (KRd) as a consolidation regimen in transplant-eligible patients who had notachieved MRD negativity following ASCT.